Heidi, the Melbourne AI medical scribe company, has raised $340 million in new capital. The money comes in two parts. A $100 million Series C led by Blackbird values the company at $900 million, double its last mark, with Phoenix Court, Point72 Private Investments and Headline joining. On top of that, General Catalyst’s Customer Value Fund is putting in $240 million of growth capital. Total funding now stands at about $437 million.
The numbers behind it
Heidi’s usage is large for a company this young. It supports about 2.8 million patient visits a week and 175 million to date, across 190 countries and 110 languages. The company says it has saved clinicians 67 million hours. Its Evidence tool, a point-of-care research assistant launched in March, has already handled more than 10 million queries.
Customers include Beth Israel Lahey Health in the US, and Heidi is the sole supplier for NHS England Midlands. At home it runs in every emergency department in New Zealand and at hospitals including the Royal Children’s Hospital Melbourne.
From notes to actions
The scribe was the way in. Heidi listens to the consultation and writes the notes. The new money is about going past documentation into what the company calls supervised agentic work: filling in order sets, drafting referrals and pulling together a patient’s history before the visit starts. A clinician still signs off, but the software does the typing and the chasing.
Founder and CEO Dr. Thomas Kelly, a physician, framed it as moving from documenting care to helping clinicians act on it, with the goal of getting an AI care partner to every doctor.
A crowded field
Ambient scribes are one of the few AI categories in healthcare with real adoption. That also makes it crowded. Microsoft’s Dragon Copilot, Abridge and a long list of others are selling into the same health systems. Heidi’s edge has been price and reach outside the US, where it signed national and regional deals faster than US-focused rivals.
The General Catalyst piece is worth noting. Its Customer Value Fund backs companies with proven customer economics and gets repaid from revenue. That kind of money doesn’t go to a pilot-stage startup.
The scribe war is mostly won by whoever is already in the room. Heidi now has the money to stay there.